An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension.

Trial Profile

An 8-Month Phase 3, Open-Label Study With a Blinded Reversal Phase to Evaluate the Safety and Tolerability of TAK-491 in Subjects With Essential Hypertension.

Completed
Phase of Trial: Phase III

Latest Information Update: 24 Jan 2015

At a glance

  • Drugs Azilsartan medoxomil (Primary)
  • Indications Essential hypertension
  • Focus Registrational; Therapeutic Use
  • Sponsors Takeda Global Research and Development Center
  • Most Recent Events

    • 21 Jul 2010 Additional trial identifier U1111-1113-9088 identified as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Actual patient number (418) added as reported by ClinicalTrials.gov.
    • 26 Jun 2009 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top